C12N 2770/32671
Demonstrated in vivo effect
C12N2770/32671 (Demonstrated in vivo effect) appears on 12 US grants and 23 published applications in this corpus.
Search patents in C12N- Granted patents
- 12
- Published applications
- 23
- Assignees
- 8
- Inventors
- 38
- Latest grant
- 14 Nov 2023
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2010 | 0 | 3 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 2 | 2 |
| 2016 | 1 | 1 |
| 2017 | 1 | 3 |
| 2018 | 1 | 0 |
| 2019 | 2 | 3 |
| 2020 | 1 | 2 |
| 2021 | 1 | 2 |
| 2022 | 2 | 4 |
| 2023 | 1 | 1 |
| 2024 | 0 | 2 |
By publication year.
Recent patents
- Oncolytic poliovirus for human tumors14 Nov 2023US 11,813,298 B2Duke University
- Methods for predicting tumor response to immunotherapy30 Aug 2022US 11,428,691 B2Duke University
- Oncolytic poliovirus for human tumors9 Aug 2022US 11,406,677 B2Duke University
- Attenuated viruses useful for vaccines2 Nov 2021US 11,162,080 B2The Research Foundation for The State University of New York
- Oncolytic poliovirus for human tumors13 Oct 2020US 10,799,543 B2Duke University
- Attenuated viruses useful for vaccines11 Jul 2024US 2024/0228981 A1The Research Foundation for The State University of New York
- Vaccination against coronavirus with poliomyelitis vaccine4 Jan 2024US 2024/0000923 A1E-MO Biology Inc.
- Recombinant enteroviruses and uses thereof27 Jul 2023US 2023/0233669 A1Aleph Therapeutics, Inc.
- Newcastle disease virus-based vectored vaccine22 Dec 2022US 2022/0402975 A1
- Oncolytic Poliovirus for Human Tumors27 Oct 2022US 2022/0339223 A1Duke University
Most cited
By later US patents
- Attenuated viruses useful for vaccines13US 9,476,032 B2The Research Foundation for The State University of New York · 2016
- Vaccine5US 8,945,582 B2Glaxosmithkline Biologicals SA · 2015
- Inactivated polio vaccines4US 8,956,625 B2Glaxosmithkline Biologicals SA · 2015
- Methods of making modified viral genomes2US 10,023,845 B2The Research Foundation for The State University of New York · 2018
- Oncolytic poliovirus for human tumors2US 10,398,743 B2Duke University · 2019